GLP1R and diabetes mellitus: During the last two decades, incretin-based therapies (glucagon-like peptide 1 receptor agonists (GLP-1 RA) and dipeptidyl peptidase inhibitors (DPP-4i)) have provided safe and effective treatment options for patients with diabetes, along with beneficial effects such as weight loss2.